Matthew Lee, MD
Urology · Columbus, OHNPI 1427457480
Payments from drug & device makers
Across 44 payments — averaging $362.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$12K
- Richard Wolf Medical Instruments Corp.$2K
- Calyxo, Inc.$330
- Amgen$303
- Seagen Inc.$288
- KARL Storz Endoscopy-america$266
- plus $562 from 5 others
What the payments were for
- Consulting fees$5,92537%
- Speaking & faculty fees$6,58341%
- Travel & lodging$6954%
- Food & beverage$2,56016%
- Education$1781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 23 | $11,716 |
| Richard Wolf Medical Instruments Corp. | 5 | $2,476 |
| Calyxo, Inc. | 3 | $330 |
| Amgen | 3 | $303 |
| Seagen Inc. | 2 | $288 |
| KARL Storz Endoscopy-america | 2 | $266 |
| Medtronic | 2 | $253 |
| Johnson & Johnson | 1 | $125 |
| Stryker | 1 | $75 |
| Lumenis, Inc | 1 | $70 |
| Baxter Healthcare | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$6,416
- Moses 550 D\F\L$2,800
- Lumenis Pulse 120H$1,720
- CVAC Aspiration System$289
- TUKYSA$288
- INTERSTIM$253
- N/A$183
- Urology Instrumentation$145
- Moses 550 DFL$133
- XARELTO$125
- LUMAKRAS$125
How this compares
$15,940 in reported general payments places this provider in the 80th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 97 | $56,132 |
| Methenamine Hippurate | 38 | $1,262 |
| Oxybutynin Chloride ErOxybutynin Chloride | 36 | $1,108 |
| Tamsulosin Hcl | 66 | $488 |
| Solifenacin Succinate | 12 | $259 |
| Finasteride | 37 | $247 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $119 |
| Chlorthalidone | 11 | $103 |
| Diclofenac Sodium | 14 | $39 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other urology in Columbus
- Eric SingerColumbus$2.1M
- Bodo KnudsenColumbus$267K
- Debasish SundiColumbus$176K
- Iryna CrescenzeColumbus$156K
- Courtenay MooreColumbus$153K
- Nicholas TadrosColumbus$110K
- Gregory LoweColumbus$106K
- Ahmad ShabsighColumbus$80K
- George HoColumbus$72K
- Hiren PatelColumbus$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.